(CercleFinance.com) – Sanofi announces that its Beyfortus has reduced the risk of hospitalizations due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared to those who have not been immunized against RSV.
These positive data, published in The Lancet, are the interim results of the ongoing NIRSE-GAL study, a three-year study carried out in Galicia. They correspond to the first season of VRS circulation since the introduction of the Beyfortus.
These results support the data obtained within the framework of pivotal clinical studies and the phase IIIb HARMONIE clinical trial, carried out in conditions close to real life, having demonstrated the high effectiveness of Beyfortus.